Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

EyeMax: a new IOL for patients with cataract and macular disease

Search Title by author or title

Session Details

Session Title: New IOLs: Material & Preload IOL

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 08:06

Venue: Room A3, Podium 2

First Author: : F.Badala ITALY

Co Author(s): :    E. Moretti   E. Bona                 

Abstract Details


To determine safety and efficacy of a new intraocular implant, EyeMax (London Eye Hospital Pharma; London, UK) in cataract patients with dry and stable wet macular degeneration (AMD) .


Micro Chirurgia Oculare Milano


A prospective case series of 109 eyes (72 patients) with cataract and AMD that underwent standard phacoemulsification with EyeMax IOL implantation and had at least 6 months follow-up. Outcomes were distant and near visual acuity, intra- and postoperative complications. The EyeMax IOL is an injectable hydrophilic acrylic IOL designed to improve the quality of the retinal image in all areas of the macula up to 10 degrees from fixation.


Visual acuity improved significantly in all patients, for both distance (mean gain: 18 ETDRS letters) and near (mean gain: 26 ETDRS letters). Patients implanted bilaterally had the best visual outcome. All patients were left intentionally hyperopic to get additional magnification from spectacle correction. No intra- or postop complications were encountered.


The EyeMax IOL shows promising results in improving distance and near vision in eyes with cataracts and macular degeneration. Near visual acuity seems to benefit more than distance visual acuity. Patients implanted bilaterally seems to get a better outcome.

Financial Disclosure:


Back to previous